CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis

Jian Zhang, Lalit Patel, Kenneth J. Pienta

Research output: Contribution to journalArticle

Abstract

CCL2 is a chemokine known to recruit monocytes and macrophages to sites of inflammation. A growing body of research suggests CCL2 is progressively overexpressed in tumor beds and may play a role in the clinical progression of solid tumors. Cancer cells derived from several solid tumor types demonstrate functional receptors for CCL2, suggesting this chemokine may achieve tumorigenicity through direct effects on malignant cells; however, a variety of normal host cells that co-exist with cancer in the tumor microenvironment also respond to CCL2. These cells include macrophages, osteoclasts, endothelial cells, T-lymphocytes, and myeloid-derived immune suppressor cells (MDSCs). CCL2 mediated interactions between normal and malignant cells in the tumor microenvironment and plays a multi-faceted role in tumor progression.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalCytokine and Growth Factor Reviews
Volume21
Issue number1
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

    Fingerprint

Keywords

  • CCL2
  • CCR2
  • Metastasis
  • Prostate cancer
  • Tumorigenesis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this